Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
51.21
+0.86 (1.71%)
Jun 24, 2026, 3:59 PM EST
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$773,849
Profits / Employee
$157,320
Market Cap
326.25B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Veradigm | 2,300 |
| American Oncology Network | 1,914 |
| Glass House Brands | 426 |
| Northwest Biotherapeutics | 105 |
| Silence Therapeutics | 88 |
| Elite Pharmaceuticals | 68 |
| CytoDyn | 13 |
Roche Holding AG News
- 5 days ago - The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs - WSJ
- 5 days ago - U.S. opens tariff probe targeting Germany's drug pricing policies - CNBC
- 6 days ago - FDA accepts supplemental Biologics License Application for Roche's Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma - GlobeNewsWire
- 6 days ago - FDA Accepts Supplemental Biologics License Application for Genentech's Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma - Business Wire
- 7 days ago - FDA approves first generic version of Roche's flu drug - Reuters
- 11 days ago - Drugmakers race to find a place in the next wave of obesity drugs - CNBC
- 13 days ago - FDA Grants Priority Review for Genentech's Tecentriq for a Certain Type of Stage III Colon Cancer - Business Wire
- 13 days ago - Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies - PRNewsWire